Published in Hematology Am Soc Hematol Educ Program on January 01, 2004
Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood (2014) 1.19
Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev (2012) 1.14
Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells. Cancer Res (2009) 1.10
Primary diffuse large B-cell lymphoma of the ascending colon. Rare Tumors (2013) 0.97
Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma (2013) 0.95
Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean J Hematol (2010) 0.90
Disrupting the networks of cancer. Clin Cancer Res (2012) 0.90
Diffuse large B-cell lymphoma, not otherwise specified of the palate: A case report. J Clin Exp Dent (2013) 0.81
Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. Eur Oncol Haematol (2012) 0.78
Administration of vincristine in a patient with Machado-Joseph disease. Oncology (2012) 0.77
Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma. Acad Radiol (2013) 0.76
NonHodgkin's Lymphoma with Peritoneal Localization. Case Rep Gastrointest Med (2014) 0.75
Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. Oncotarget (2016) 0.75
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol (2002) 2.88
New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol (2005) 2.40
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol (2006) 2.38
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res (2005) 2.37
Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol (2004) 2.23
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood (2008) 2.14
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol (2008) 2.11
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol (2012) 1.99
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood (2013) 1.72
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood (2012) 1.67
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood (2007) 1.60
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res (2012) 1.60
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol (2008) 1.56
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol (2011) 1.47
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood (2008) 1.45
Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs (2002) 1.45
Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Invest (2007) 1.33
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood (2005) 1.28
Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma (2010) 1.28
Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther (2005) 1.23
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood (2011) 1.22
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol (2007) 1.20
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res (2006) 1.18
Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest (2003) 1.17
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2012) 1.17
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res (2012) 1.17
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer (2012) 1.16
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood (2012) 1.15
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma (2009) 1.14
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol (2010) 1.11
Brentuximab vedotin. Clin Cancer Res (2012) 1.10
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood (2011) 1.10
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res (2010) 1.10
Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res (2010) 1.09
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica (2012) 1.09
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol (2005) 1.07
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol (2009) 1.06
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol (2003) 1.06
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs (2010) 1.05
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem (2005) 1.04
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol (2006) 1.02
New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr Opin Hematol (2011) 1.01
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid (2011) 1.00
Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia. Ann Surg Oncol (2009) 0.98
The limits of limited stage lymphoma. J Clin Oncol (2004) 0.96
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation (2008) 0.95
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma (2005) 0.95
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res (2010) 0.94
Pralatrexate pharmacology and clinical development. Clin Cancer Res (2013) 0.91
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol (2013) 0.91
A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients. Leuk Lymphoma (2009) 0.89
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood (2013) 0.89
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study. Cancer (2012) 0.89
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br J Haematol (2009) 0.87
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol (2014) 0.86
Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs (2006) 0.86
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol (2013) 0.86
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res (2013) 0.86
Mantle cell lymphoma in relapse: the role of emerging new drugs. Curr Opin Oncol (2010) 0.85
PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer (2013) 0.84
New strategies in the treatment of mantle cell lymphoma. Clin Cancer Res (2012) 0.83
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma. Br J Haematol (2012) 0.82
Localized large cell lymphoma: is there any need for radiation therapy? Curr Opin Oncol (2009) 0.82
Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Rev Hematol (2010) 0.82
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer (2011) 0.82
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk (2012) 0.82
New drugs for the treatment of lymphoma. Hematol Oncol Clin North Am (2008) 0.81
Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection. Leuk Lymphoma (2015) 0.81
Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs? Curr Oncol Rep (2015) 0.80
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res (2011) 0.80
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. Am J Hematol (2014) 0.80
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk (2011) 0.79
Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions. Blood (2009) 0.79
Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Leuk Lymphoma (2007) 0.79
Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas. Clin Cancer Res (2012) 0.79
Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol (2012) 0.78
Targeting survival pathways in lymphoma. Adv Exp Med Biol (2010) 0.78
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma (2010) 0.78
Lack of cost-effectiveness of omalizumab. J Allergy Clin Immunol (2005) 0.78
Plasmablastic lymphoma of the stomach. Clin Adv Hematol Oncol (2012) 0.78